Is URGN or VERA more undervalued in 2026?

CirclFi compares UroGen Pharma Ltd. (URGN) and Vera Therapeutics, Inc. (VERA) using 13 institutional-grade valuation models. URGN has a Quality of Company score of 6.5/10 while VERA scores 4.6/10.

Which is a better buy — URGN or VERA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do URGN and VERA valuations compare?

URGN at $28.69 and VERA at $35.86 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

URGN vs VERA Valuation Comparison 2026 — Intrinsic Value Analysis

URGN

Biotechnology

UroGen Pharma Ltd.

Quality

6.5

out of 10

Value Trap

SAFE

Price

$28.69

Last close

Models

11/13

Active

VERA

Biotechnology

Vera Therapeutics, Inc.

Quality

4.6

out of 10

Value Trap

SAFE

Price

$35.86

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	URGN Fair Value	URGN Upside	VERA Fair Value	VERA Upside
Bayesian DCF	Intrinsic	$7.27	-74.7%	$11.25	-68.6%
Earnings Power Value	Intrinsic	$3.35	-85.4%	$15.75	-58.2%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for URGN vs VERA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

URGN vs VERA — Which Stock Is More Undervalued?

URGN scores higher with a 6.5/10 quality rating vs VERA's 4.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing UroGen Pharma Ltd. (URGN) and Vera Therapeutics, Inc. (VERA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

URGN currently trades at $28.69 with a QOC of 6.5/10, while VERA trades at $35.86 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).